Skip to main content
. 2023 Jun 22;14:1171978. doi: 10.3389/fimmu.2023.1171978

Figure 2.

Figure 2

The expression of TLS-kines in association with patients clinical outcome. Kaplan Meier plots depicting OS probability for TCGA-SKCM (n = 426) patients stratified based on expression of (A) APRIL/TNFSF13, (B) CXCL10, (C) CXCL13 or (D) CCL19. High expression of APRIL/TNFSF13 (HR: 0.72 95%, CI: 0.55-0.94; p = 0.018), CXCL13 (HR: 0.58 95%, CI: 0.44-0.76; p < 0.001), CXCL10 (HR: 0.51, 95% CI: 0.39-0.68; p < 0.001) were significantly associated with improved OS in TCGA-SKCM patients. (E) Cox multivariable model after adjusting for age, AJCC stage and APRIL/TNFSF13 expression. (F) Kaplan Meier plot of APRIL/TNFSF13 expression in Moffit cohort. High expression showed a significant better OS than lower expression (p-value < 0.05). (G) Forest plot for the Cox proportional hazard model when adjusting for CXCL13, APRIL/TNFSF13, the average expression groups of CXCL13 + APRIL/TNFSF13, the average expression groups of CXCL13 + APRIL/TNFSF13 + CXCL10, AJCC Stage and age. The average expression of the combined gene signature APRIL/TNFSF13 + CXCL10 + CXCL13 showed an independent prediction of OS along with age and AJCC stage (p-value < 0.05).